Cancer survivors of childhood brain tumours show significant deficits in intelligence, educational achievement and employment, even decades after treatment, an unprecedented study at St Jude Children's Research Hospital has found.
Bioness has announced the successful results from the company's one-year clinical trial of the StimRouter neuromodulation system, published in Neuromodulation.
The treatment was shown to have similar survival rates to conventional radiotherapy in a study published in The Lancet Oncology.
People taking natalizumab for the treatment of multiple sclerosis may be at a heightened risk of developing of progressive multifocal leukoencephalopathy.
This funding will be used to complete ongoing clinical trials and filing of product de novo with the FDA, as well as funding CE mark registration in the EU, for BrainPulse.
Using Rapid Medical's proprietary technology, this stent retriever is designed to be fully visible and controllable. The device can be adjusted by physicians to fit the dimensions of blood vessels causing acute ischaemic stroke, and is the first of its kind, according to the company.
This intracranial stereotactic radiosurgery system is designed to offer precision radiosurgery to more patients with a wider variety of types and sizes of tumour.
Thomas Liebig reported that a first-line aspiration approach with MicroVention's Sofia device is "worth a try" because it is associated with similar results to first-line aspiration approaches with other dedicated intermediate catheters, and unsuccessful aspiration with Sofia can be "easily converted" into stent retriever-based therapy.
The study evaluates the company's Reprieve wireless neurostimulation device, with a view to CE mark accreditation for multiple clinical indications.
The phase 2 study appears to demonstrate acceptable safety and increased glucose metabolism in the treatment of patients with mild Alzheimer's disease.dbsf
The closed-loop responsive neurostimulation system recieved the award at the 2015 Phoenix Medical Device CEO Conference
Seven centres are first in USA to order Icon, which features the first integrated stereotactic cone beam CT imaging, online adaptive dose evaluation and planning enabling the most accurate delivery of frameless and frame-based treatments, according to Elekta.
Sequent Medical has announced that the US Food and Drug Administration has approved the inclusion of WEB .021" devices for use in its US Investigational Device Exemption (IDE) clinical study called WEB-IT.
One of the newest devices to surface for the treatment of acute ischaemic stroke is the EmboTrap from Neuravi. At the World Live Neurovascular Course (WLNC; 8-10 June, Chicago, USA) Osama Zaidat and Tommy Andersson introduced the device and presented the results of the first 25 cases performed by Andersson and the team at Karolinska in Sweden.
In the first study to be published reporting on endovascular aneurysm treatment with the p64 flow modulation device (Phenox), Francesco Briganti and colleagues have found that the device provides a safe procedure with no technical complications.
Emory Saint Joseph's Hospital, Atlanta, USA, is improving treatment for stroke patients with the launch of a Telestroke programme, which allows neurologists to remotely evaluate patients around the clock through real-time conferencing with a Telerobot monitor.
The finding could lead to more highly targeted research and, eventually, new treatments for the debilitating neurological disorder, which robs people of their memories.
The research, conducted on a mouse model and in human cells, found that a stress-coping hormone released by the brain boosts the production of protein fragments.
The disease may cause different pathologies in African-Americans than in white Americans of European descent, according to a study published in an online issue of the medical journal of the American Academy of Neurology.
Three medical centres in the United Kingdom and Germany have ordered and are now planning upgrades to Elekta's latest generation stereotactic radiosurgery system for the brain, Leksell Gamma Knife Icon.
Uric acid-a chemical that at high levels can lead to serious illness-may lessen women's disability after stroke, according to new research in the American Heart Association's journal Stroke.
Southend University Hospital established an innovative interventional stroke service using the ANGIO Mentor Suite simulator at Anglia Ruskin University.
To give Parkinson's patients another in-home option, Johns Hopkins graduate students have invented a headband-shaped device to deliver noninvasive brain stimulation to help reduce the symptoms.
In both black and white patients, having had a stroke meant that their score on a 27-item test of memory and thinking speed had dropped as much as it would have if they had aged 7.9 years overnight.
New data demonstrating the efficacy of Brainsway's Deep TMS for the treatment of ADHD and OCD have been presented at the Society of Biological Psychiatry Annual Scientific Meeting ( 14-16 May, Toronto, Canada).
Nevro has announced that it has received approval from the United States Food and Drug Administration (FDA) for its Senza spinal cord stimulation system....
People with haemorrhagic strokes are more likely to survive if they are treated at a comprehensive stroke centre, according to research published in the Journal of the American Heart Association.
Flowonix Medical has announced that the first implants of its Prometra II intrathecal infusion pump took place on 5 May, 2015 at St Francis Hospital in Charleston, USA.
DePuy Synthes CMF has announced the launch of Synthecel Dura Repair, the first commercially available biosynthesised dural replacement derived from cellulose for use in neurosurgery.
On 14 May at a meeting of EUROHEADPAIN Cefaly Technology will present three significant patent pending systems of neuromodulation that are in development
Medtronic plc has announced that it has received clearance from the US Food and Drug Administration (FDA) for expanded indications of specific StealthStation electromagnetic surgical navigation system instruments for paediatric and adult cranial and ENT procedures.
Now complete, the acquisition of Spinal Modulation adds DRG stimulation technology to the St Jude Medical chronic pain portfolio.
Stem cells are a safe therapy for patients with amyotrophic lateral sclerosis (ALS), according to the results of a recently completed phase 1 clinical trial.
By looking at the brain, scientists believe it is now possible to distinguish between two very different conditions that can have very similar symptoms.
Monteris Medical has announced the launch of two new reduced diameter mini-probes for its NeuroBlate System, a minimally invasive robotic laser thermotherapy tool.
The Enterprise 2 system is the latest generation of the company's self-expanding stent and delivery system used to treat wide-necked intracranial aneurysms and to help maintain the position of endovascular coils.
The American Academy of Neurology (AAN) has elected Terrence L Cascino, Mayo Clinic of Rochester, USA, as its 34th president.
As part of the agreement, Boston Scientific will begin distributing the Brainlab deep brain stimulation surgical planning portfolio with the Boston Scientific Vercise deep brain stimulation system in select countries.
The company's efforts are focused on the implementation of design changes to the SynchroMed drug infusion pump to address issues the company has previously communicated, and on enhancing the Neuromodulation quality system.
With the introduction of Elekta's new Leksell Gamma Knife Icon, the benefits of precision cranial radiosurgery are now available for more patients with a wider variety of tumour types and sizes.
A new study led by scientists from Beth Israel Deaconess Medical Center and Boston University School of Medicine, USA, suggests that long-term exposure can cause damage to brain structures and impair cognitive function in middle-aged and older adults.
Interventional treatments-especially surgery-provide good functional outcomes and a high cure rate for patients with lower-grade arteriovenous malformations of the brain, reports the May issue of Neurosurgery.
In relapsing remitting multiple sclerosis (RRMS) patients treated with Lemtrada in the phase III pivotal studies, MRI effects observed in the two-year trials were maintained through two additional years in the extension study (years three and four).
The expanded approval for full-body MRI scans applies to all patients receiving a new system and to an estimated 13,000 people in Europe already receiving Medtronic DBS therapy.
The Alcyone MEMS cannula is a dual-lumen, MRI-compatible injection and aspiration cannula for use in the brain.
A pair of topical medicines already alleviating skin conditions each may prove to have another, even more compelling use: instructing stem cells in the brain to reverse damage caused by multiple sclerosis.
The study of NeuroVive's drug candidate NeuroSTAT will continue as planned and move on to the next dosage group following endorsement from the independent safety committee.
BrainStorm Cell Therapeutics presented results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) at a poster session at the American Academy of Neurology annual meeting, in Washington, DC, USA.
Following the completion of this acquisition, St Jude Medical will become the only medical device manufacturer to offer radiofrequency ablation (RFA), spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation therapy solutions for the treatment of chronic pain.
Use of either proximal embolic protection devices or distal filter embolic protection devices during elective carotid artery stenting results in low rates of in-hospital stroke and death, according to a new study.
With the publication of two more stroke trials, the evidence in favour of endovascular treatment in patients with acute ischaemic stroke has reached new heights. Data from SWIFT PRIME and REVASCAT add to that of three other trials-MR CLEAN, EXTEND-IA and ESCAPE-that have begun to change the face of ischaemic stroke treatment.
Silk Road Medical has announced the first US commercial procedure using the Enroute transcarotid neuroprotection system was successfully performed at Mills-Peninsula Medical Center in Burlingame, USA by vascular surgeon John E Rosenman.
The IDEAS study will assess the impact of brain amyloid PET imaging on a variety of patient outcomes.
Three prominent neurosurgeons will review their clinical experience using real-time navigated laser therapy for brain lesion ablation within intraoperative MRI suites at the upcoming 83rd American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.
The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute have announced that they are collaborating with GlaxoSmithKline on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients.
After analysing stroke treatment records, researchers at Rhode Island Hospital in collaboration with researchers from the University of Cincinnati, both USA, learned that women and men have different reasons for being excluded from receiving the common clot-dissolving drug, recombinant tissue plasminogen activator (rt-PA).
Jan Medical’s Nautilus BrainPulse detected cerebral vasospasm with clinically meaningful accuracy...
A clinical study published in Neurocritical Care demonstrated that Nautilus BrainPulse is a highly sensitive skull accelerometry that can detect cerebral vasospasm "with clinically meaningful accuracy".
A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer's disease, researchers at Johns Hopkins University found.
The partnership, in addition to co-product development, will support distribution of Stimwave's Wireless Pain Relief technology, which became available in the USA in January 2015.
New University of Houston research has demonstrated that an amputee can grasp with a bionic hand, powered only by his thoughts.
Racz has been honoured with several lifetime achievement awards from societies throughout the world in recognition of contributions that span more than five decades.
The three groups endorse the approach in their article, "MR CLEAN: past the tipping point of clinical equipoise," by Henry H Woo et al, published online, ahead of print, in the Journal of Neurosurgery.
The first-ever randomised, controlled trial to compare spinal cord stimulation technologies found that high-frequency stimulation using 10kHz (HF10) exceeded lower-frequency, traditional stimulation in response rate and pain relief.
IMRIS Inc has announced that VISIUS iCT, the first and only ceiling-mounted intraoperative computed tomography scanner, has received Health Canada licensing allowing for sales and marketing in the country.
The VISSIT study has shown that among patients with symptomatic intracranial arterial stenosis, the use of a balloon-expandable stent compared with medical therapy (clopidogrel and aspirin) resulted in an increase of stroke or transient ischaemic attack.
An experimental drug that attacks brain tumour tissue by crippling the cells' energy source called the mitochondria has passed early tests in animal models and human tissue cultures, say Houston Methodist scientists.
A year-long study shows that Acoustic CR neuromodulation treatment is effective in reducing tonal tinnitus symptoms such as severity and loudness and annoyance by nearly 40%.
Decreased ability to identify specific odours can predict abnormal neuroimaging results in blast-injured troops, according to a new study by US federal researchers released online in the journal Neurology.
A research team at UC San Francisco has discovered an RNA molecule called Pnky that can be manipulated to increase the production of neurons from neural stem cells.
By 2030, chronic subdural haemorrhage will be the most common adult brain condition requiring neurosurgical intervention in the USA, and hospitals and neurosurgeons may be under-manned to handle the projected onslaught of patients, a new study says.
Researchers at Mayo Clinic developed a new scoring system to help determine which elderly people may be at a higher risk of developing the memory and thinking problems that can lead to dementia.
In this study, Toca 511 is injected directly into the brain tumour through a stereotactic biopsy needle. Once injected, Toca 511 infects tumour cells, sparing healthy functioning brain cells.
In an in vitro stroke model comparison, the use of the Cover accessory device (Lazarus Effect) in conjunction with a stent retriever resulted in higher successful recanalisation rates, no embolic events and proved to be more effective than the use of a conventional guide catheter or a balloon guide catheter.
The Potamkin Prize honours researchers for their work in helping to advance the understanding of Pick's disease, Alzheimer's disease and related disorders.
Researchers at MIT have developed a method to stimulate brain tissue using external magnetic fields and injected magnetic nanoparticles-a technique allowing direct stimulation of neurons, which could be an effective treatment for a variety of neurological diseases, without the need for implants or external connections.
Neuralstem has announced top line data from the phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS).
Researchers have developed a prototype of a robotic glove which stroke sufferers can use in their own home to support rehabilitation and personal independence in receiving therapies.
Seventy-nine per cent of patients who completed the trial (15 out of 19) reported an overall improvement in their condition.
Even under optimal conditions, a large proportion of the population would be unable to access a stroke centre within this window, according to a new study.
The mouth guards were able to measure six degrees of freedom, including rotational movement (roll, pitch, and yaw), while current safety standards use three degrees of freedom.
A study of a direct brain responsive neurostimulator found that responsive direct cortical stimulation reduces seizures and improves quality of life over an average of 5.4 years for for partial onset seizures that cannot be controlled with medication
In early use of the Medina coil system, researchers have found the device to be a next generation coil that combines the familiar procedural safety and technique associated with conventional coils, with improved circumferential aneurysm filling, which, they say, it is thought will lead to improved long-term outcomes.
Reversal of international normalised ratio below a certain level and systolic blood pressure less than 160mmHg at four hours were associated with lower rates of haemorrhage enlargement in oral anticoagulation-associated intracerebral haemorrhage patients, according to a new study.
A new study has found that people who slept more than eight hours a night were 46% more likely to have a stroke than people who slept six to eight hours a night.
The StimRouter is a minimally invasive implantable device designed to reduce pain by specifically targeting the affected peripheral nerve.
Advanced Uro-Solutions develops and manufactures the NURO percutaneous tibial nerve stimulation system for patients with overactive bladder and associated symptoms.
Patients who were aspirin resistant also had larger areas of the brain affected by the stroke, as measured by MRI diffusion weighted imaging.
Medtronic DBS therapy for epilepsy was associated with a sustained and statistically significant reduction in seizure frequency from baseline that continued to improve over time: 69% median seizure reduction from baseline at five years and 41% at one year.
Saluda Medical has announced that it has received US$10 million in Series B financing bringing a breakthrough treatment for chronic pain one step closer to reality.
Preclinical study results pave the way for newly-opened clinical trial of immune cells engineered to attack protein found on tumours in 30% of patients with glioblastoma.
Research presented at the American Stroke Association's International Stroke Conference (Nashville, USA, 11-13 February, 2015) suggests that a new device inserted into small ruptured brain aneurysms significantly improved healing of ruptured aneurysms compared to a standard device.
The results, presented at the International Stroke Conference (Nashville, USA, 11-13 February, 2015) are expected to substantially improve both the study and treatment of stroke.
The distribution agreement gives Caputron Medical the rights to market the Neuro-MS/D Diagnostic, Therapeutic, and Advanced Therapeutic rTMS stimulators in the USA and Canada.
The two organisations will work together over several years to educate, raise awareness and support effective management of patients who have strokes.
Those who received the stem cell transplants had 80% fewer new areas of T2 lesions than those who received mitoxantrone.
More ischaemic stroke patients are now being quickly transferred to certified US stroke centres, according to research presented at the American Stroke Association's International Stroke Conference 2015.
There was a significant reduction of median alarm to CT scan completion times-41 minutes in MSTU vs. 62 minutes in emergency room patients.
Two new clinical trials on the treatment of stroke (ESCAPE and EXTEND IA) demonstrate that neurointerventional surgery significantly increases the number of patients who are able to live independently without major neurological disabilities.
Treatment with creatine monohydrate for at least five years for patients with early and treated Parkinson's disease failed to slow clinical progression of the disease, compared with placebo, according to a study in JAMA.
Investigators used lab-grown oligodentrocyte progenitor cells to treat rats that had been exposed to brain irradiation.
The Enroute system (Silk Road Medical) is a first in class system used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while performing carotid angioplasty and stenting.
A multicentre double blinded randomised controlled trial has shown Brainsway deep TMS (transcranial magnetic stimulation) to be efficacious and safe for drug-resistant depression, with a stable effect over three months of maintenance treatment.
Designed to divert blood flow away from an aneurysm, the Pipeline Flex embolisation device (Medtronic) features a braided cylindrical mesh tube that is implanted across the base or neck of the aneurysm.
According to a recent retrospective review published in the Journal of NeuroInterventional Surgery, the transradial approach to mechanical embolectomy is a valid approach for the endovascular treatment of acute ischaemic stroke.
Long-term treatment study data show sustained effectiveness in adults historically resistant to other treatments.
BrainStorm announces positive DSMB recommendation in ongoing NurOwn amyotrophic lateral sclerosis...
The DSMB did not find any lab abnormalities, adverse events or significant protocol deviations that would be cause for concern.
In a study of 11,644 middle-aged Swedish twins who were followed for 43 years, researchers compared the effects of an average of more than two drinks daily to less than half a drink daily.
60Hz stimulation more effective than standard treatment at improving swallowing and gait issues
The review examined the efficacy of both surgically implanted non-invasive vagus nerve stimulation, including electroCore's gammaCore device.
Brain imaging can help predict an individual’s future learning, criminality, health-related behaviours, and response to drug or behavioural treatments.
Treatment with nonmyeloablative hematopoietic stem cell transplantation was associated with improvement in measures of disability and quality of life
This sale involves both radiology and MRI systems in four hybrid operating rooms for the hospital’s new imaging centre with clinical opening planned in 2016.
Researchers have identified a protective mechanism that activates when body temperature is lowered, initiating a process that prevents the loss of brain cells and the connections between them.
This is the company's first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold to treat patients with acute spinal cord injury.
Ischaemic micro-lesions associated with flow-diverting stents in treatment of intracranial aneurysms
Researchers from Dupuytren University Hospital, Limoges, France, conducted a study to determine the extent of these complications and their implications on clinical outcomes in flow-diverting stent treatments.
New research at the University of Cincinnati Neuroscience Institute has shown that spreading depolarisations can be measured by the placement of electroencephalograph (EEG) electrodes on the scalp. Head of the research team, Jed Hartings speaks to NeuroNews about the discovery and its potential to change current practice.
Initial experience with PulseRider (Pulsar Vascular) has shown the device to be safe and effective as an adjunct in the treatment of bifurcation aneurysms arising at the basilar apex or carotid terminus.
BrainScope has announced the publication of an independent study that demonstrated the potential clinical utility of its traumatic brain injury technology to identify acute stroke in the hospital Emergency Department setting.
Cyberonics has announced the receipt of a decision from the Departmental Appeals Board (DAB) of the Department of Health and Human Services in the USA.
A major breakthrough in the development of stem cell-derived brain cells has put researchers on a firm path towards the first ever stem cell transplantations in people with Parkinson's disease.
Exercise may help people with Parkinson's disease improve their balance, ability to move around and quality of life, even if it does not reduce their risk of falling, according to a new study published in the online issue of Neurology.
Stroke has dropped from the USA's fourth-leading cause of death to No. 5, according to new federal statistics.
Three-year outcomes suggest that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis.
NeuroMetrix will unveil and demonstrate Quell, a novel wearable pain relief device at the 2015 International Consumer Electronics show.
The Challenge has teams competing to commercialise 16 National Institutes of Health-conceived and -developed inventions involving therapeutics, diagnostics, prognostics, and medical devices for a range of brain diseases.
Rogawski is an internationally recognised expert on treatments for seizures and epilepsy.
The standard treatment for newborns whose brains were deprived of oxygen appears to work better than proposed alternatives, according to a study from a National Institutes of Health research network.
The EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Xadago (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilised on 'Standard of Care'.
For the first time, the Multicentre randomised clinical trial of endovascular treatment for acute ischaemic stroke in the Netherlands (MR CLEAN) has shown better outcomes in favour of intervention in patients with acute ischaemic stroke.
The AAN supports the reclassification of marijuana-based products by the federal government to improve access for study of marijuana or cannabinoids under approved research protocols.
Adaptive Hybrid Surgery and Automatic Brain Metastases Planning software by Brainlab are now available in the USA after successful clinical use in several international markets.
The figures released by the HSCIC show that the percentage of patients admitted to an acute stroke unit within four hours of arrival at hospital varied from 22% to 85% across different clinical commissioning groups.
The E-36 and E-37 studies assessed the acute impact of the AspireSR generator on seizure duration and termination, as well as the long-term evaluation of safety, clinical benefit of the automatic stimulation feature, and quality of life.
Brainsway has announced that it has received an IDE (Investigational Device Exemptions) approval from the FDA for launching a multicentre trial which will examine the effectiveness of Brainsway's Deep TMS (deep transcranial magnetic stimulation) for treating PTSD (post-traumatic stress disorder) patients.
At the 18th annual North American Neuromodulation Society (NANS) congress, researchers presented 20 international, peer-reviewed scientific abstracts from Australia and Europe highlighting clinical results of the Axium neurostimulator system for the treatment of chronic, intractable pain.
People with a high level of education who complain about memory lapses have a higher risk for stroke, according to new research in the American Heart Association journal Stroke.
Acorda Therapeutics has enrolled its first patient in a phase 3 study of CVT-301 for the treatment of "off" episodes in Parkinson's disease.
A CT scan of the brain within 24 hours of a mild, non-disabling stroke can predict when patients will be at the highest risk of another stroke or when symptoms may worsen.
Genzyme has announced that the first US patients have initiated treatment with Lemtrada in the commercial setting following its FDA approval for the treatment of patients with relapsing forms of multiple sclerosis.
Brainsway has announced that it has received a CE marketing approval, enabling it to immediately market and sell Brainsway deep TMS (deep transcranial magnetic stimulation) in Europe, for treatment of multiple sclerosis (MS), stroke and obsessive compulsive disorder (OCD).
The Axium system is a targeted form of spinal cord stimulation (SCS), which uses an implantable medical device to deliver mild electrical pulses that mask or interrupt pain signals as they travel from the periphery to the brain.
IMRIS has successfully completed the human factors study for the SYMBIS surgical system - the validation used to support the product's 510(k) submission to the US Food and Drug Administration.
Eli Lilly and Company and AstraZeneca have announced enrolment of the first patient into AMARANTH, a phase II/III study of an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease.
Researchers have found a specific network of brain regions that is not only more vulnerable to unhealthy ageing, for example, Alzheimer's disease, but also to disorders that emerge in young people, such as schizophrenia.
InVivo Therapeutics has announced that the Oregon Health & Science University (OHSU) in Portland, Oregon, USA, is the fifth clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI).
Researchers at The Ohio State University Wexner Medical Center are attempting to improve arm movement in stroke patients by using a transcranial magnetic stimulator (TMS) device.
Cedars-Sinai has launched the Alzheimer's Prevention Program to help identify patients at risk of developing the neurological disorder and to reduce the impact on those diagnosed with the condition.
Performed last month, the surgery involves inserting a bioresorbable scaffolding implant to act as a bridge across the gap of the injured section of the cord in an attempt to help the spinal cord heal.
A non-invasive, portable electrical device has been found to lengthen the lives of some patients suffering from glioblastoma, the most common and deadliest form of brain cancer.
The Ahead 100 from BrainScope uses a patient's electroencephalograph (EEG) to provide an interpretation of the structural condition of the patient's brain after head injury.
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke treatment and the fate of similar trials, some of which have already been halted.
It has been discovered via a UK national survey of current practice that the majority of neurosurgical units have been following most of the key recommendations for the management of aneurysmal subarachnoid haemorrhage.
Asahi Intecc has received CE certification of neurovascular guide wires: Asahi Chikai 008, Asahi Chikai black, and Asahi Chikai black 18 and is initiating sales in Europe.
The Lazarus Cover is a nitinol-mesh cover that surrounds a retriever device and captures material during removal from a blood vessel.
Accuray Incorporated has announced that studies presented at the 15th European Congress of Neurosurgical Societies (EANS) in Prague, October 12 - 17, 2014 reinforce the benefits of the CyberKnife robotic radiosurgery system for the treatment of neurological diseases such as meningiomas, acoustic neuromas, trigeminal neuralgia, and spinal tumours.
The patent application is related to the use of trigeminal nerve stimulation with minimally invasive, subcutaneously implanted electrodes and pulse generator for the treatment of a wide variety of medical disorders.
The ALS Association Board of Trustees has developed a long-term strategy for leveraging the Ice Bucket Challenge donations it has received to advance its integrated mission of leading the fight to treat and cure ALS through global research, care services and public policy.
American Shared Hospital Services has announced that the Centers for Medicare and Medicaid Services has posted its final Medicare hospital outpatient prospective payment rates for calendar year 2015. The rates for gamma knife and proton therapy remained as proposed earlier this year.
Researchers studying frontotemporal degeneration disease, a leading cause of early onset dementia, will receive more than US$30m over the next five years in grants from the National Institutes of Health (NIH).
Eating Mediterranean or DASH-style diets, regularly engaging in physical activity and keeping blood pressure under control can lower a person's risk of a first-time stroke.
Two leading neuroscientists have joined Biogen Idec to advance its research in neurodegenerative diseases.
A dynamic new assessment for helping victims of trauma to the brain, including those suffering from progressive conditions such as dementia, has been developed by a clinical neuropsychologist at the University of Leicester, UK.
Traumatic brain injury appears to be associated with an increased risk of dementia in adults 55 years and older, according to a study published online by JAMA Neurology.
In an open label trial, electroCore's handheld non-invasive vagus nerve stimulation device gammaCore, completely resolved 44.8% of migraines within 30 minutes, with an additional 11.4% experiencing moderate benefits (incomplete resolution of their headaches) by two hours.
Scientists at the Roskamp Institute have isolated a key molecule that gives researchers a new drug target for the treatment of the progressive, irreversible neurological disorder. This finding is the culmination of more than 10 years of work by more than a dozen scientists and clinicians in the research team in Sarasota.
Researchers from RegeneRx Biopharmaceuticals have reported on study findings in which thymosin beta-4 crossed the blood-brain barrier in an animal stroke model.
Costs to treat strokes caused by bleeding in the brain may increase significantly 10 years later, according to a study in the American Heart Association journal Stroke.
ALS ACT, the ALS Association, and NEALS clinical trials have announced a call for phase II clinical trial applications for novel, high-potential treatments in amyotrophic lateral sclerosis (ALS).
People with multiple sclerosis should be offered a rapid and accurate diagnosis of their condition and access to specialist advice and proven therapies, says the National Institute for Healthcare and Excellence.
Mount Sinai experts show neuroimaging tests can reveal disruptive brain changes resulting from vascular disease risk factors before the appearance of any signs or symptoms of cardiovascular or cerebrovascular disease.
Codman Neuro has launched the Spetzler Malis dual irrigating disposable non-stick bipolar forceps, the first disposable dual irrigating forceps for neurosurgery.
Using stents to keep neck arteries open is just as effective as invasive neck surgery for long-term prevention of fatal and disabling strokes, reports an international trial led by University College London.
Results from the phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014 American Neurological Association meeting.
Boston Scientific has received FDA and CE mark approval for the CoverEdge 32 and CoverEdge X 32 surgical leads, designed for use with the Precision Spectra spinal cord stimulator system.
OhioHealth "Delay the Disease" is designed to empower those living with Parkinson's disease by optimising their physical function and helping to delay the progression of symptoms associated with the disease.
The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold (InVivo Therapeutics) as well as to gather preliminary evidence of effectiveness.
NeuroSigma has has entered into a Cooperative Research and Development Agreement with the US Veterans Affairs for a phase I clinical trial to evaluate the benefits of non-invasive, external trigeminal nerve stimulation (eTNS) for patients with traumatic brain injury.
Drug-eluting balloon angioplasty shows excellent results for refractory recurrent carotid in-stent...
A long-term follow-up study reports on the safety and success of drug-eluting balloon angioplasty in treating patients with carotid in-stent restenosis that has proven refractory to treatment with balloon angioplasty and/or redo stenting.
Researchers at Lund University, Sweden, have mapped the spread of Parkinson's disease from the gut to the brain in rat models.
Treeway and Leiden Academic Center for Drug Research (LACDR) at the University of Leiden join forces and form a collaboration focused on the optimisation of clinical trial designs and data-analysis for ALS through the use of population disease progression models.
Neuravi has announced that the US Patent Office has approved two patents covering its therapeutic platform for the endovascular treatment of acute ischaemic stroke.
A previously unknown mechanism through which the brain produces new nerve cells after a stroke has been discovered at Lund University and Karolinska Institutet in Sweden.
Codman Neuro has announced the Europe, Middle East and Africa launch of the Envoy DA XB Distal Access Guiding Catheter and the 7F Envoy Guiding Catheter for neurovascular procedures.
In a rare distinction for one university, neuroimaging world leaders and University of Southern California (USC) Professors Arthur Toga and Paul Thompson will receive two major research centre awards to advance their exploration of the human brain.
IMRIS has announced that use of intraoperative imaging for optimising workflow with neurosurgical focal therapies will be featured in its exhibition space at the Congress of Neurosurgical Surgeons (CNS) meeting (20-22 October, Boston, USA).
The randomised controlled SENTINEL Trial is the first in the USA to study capture and removal of debris released during TAVI that may otherwise be the source of stroke.
Israeli biotechnology company Kadimastem has announced that it has approached the FDA regarding the cellular treatment it is developing for ALS. In the framework of talks with the FDA, Kadimastem intends to consolidate a preliminary outline for its continuing trials for this indication.
The ALS Association has approved an initial expenditure of US$21.7 million in funding to support six programmes and initiatives to expedite the search for treatments and a cure for amyotrophic lateral sclerosis (ALS). Additionally, US$12.5 million in matching donations bring the total commitment to US$34.2 million.
IMRIS announced that its horseshoe headrest has been selected one of 10 New Technology Showcase Winners by Twin Cities-based Life Sciences Alley (LSA), the USA's largest regional medical industry association.
Aethlon Medical and its diagnostic subsidiary, Exosome Sciences, have announced that a clinical collaboration with the Boston University CTE Center has been established to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.
Medina Medical has announced that it has received CE mark authorisation for its Embolization Framing Coil for commercial distribution in the European Union.
Neuralstem has announced that Jonathan D Glass presented long-term follow up data on the phase I trial testing NSI-566 human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS).
A large scale randomised clinical trial of the gammaCore therapy in chronic cluster headache not only significantly reduced the number of cluster headache attacks beyond the best available standard of care, but patients also experienced a greater reduction in number of attacks the longer they stayed on treatment.
The EBS Next Wave brain stimulation device is designed to expand the visual field of patients with impaired vision caused by glaucoma, stroke and other neurological diseases.
An experimental positron emission tomography (PET) tracer is effective in diagnosing concussion-related brain disease while a person is still alive, according to a case study.
Nexstim has announced its intention to proceed with an Initial Public Offering of Nexstim on NASDAQ OMX First North Finland and NASDAQ OMX First North Sweden ("Admission"). It is expected that the Admission will occur in the 4th Quarter of 2014.
Antisense Therapeutics has reported the publication of previously generated phase IIa clinical trial data on ATL1102 in the medical journal Neurology.
Available research evidence supports the use of deep brain stimulation for patients with obsessive-compulsive disorder who do not respond to other treatments, concludes a review in the October issue of Neurosurgery.
Researchers have discovered a defect in a key cell-signalling pathway they say contributes to both overproduction of toxic protein in the brains of Alzheimer's disease patients as well as loss of communication between neurons - both significant contributors to this type of dementia.
Positive new data have been released on a drug candidate for relapsing multiple sclerosis that was first discovered and synthesised at The Scripps Research Institute.
Boston Scientific has received CE mark approval for the Vercise deep brain stimulation system for the treatment of tremor, including the most common form of this movement disorder known as essential tremor.
Adherent Health has announced the introduction of patient support apps for two novel medications used in the treatment of seizures and epilepsy, Oxtellar XR (oxcarbazapine extended-release tablets) and Trokendi XR (topiramate extended-release capsules).
Eli Lilly and AstraZeneca have announced an agreement to co-develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.
Covidien has announced the start of enrolment in two clinical trials designed to further underscore the safety and effectiveness of the company's advanced neurovascular solutions.
This combination brought improved visualisation and workflow in removing a patient's low-grade glioma brain tumour inside a VISIUS Surgical Theatre.
PulseRider is a minimally invasive device intended for use with embolic coils in the treatment of unruptured wide-neck intracranial aneurysms originating on or near a bifurcation.
An article published in the Clinical Journal of Sport Medicine - "Detection of Concussion Using Cranial Accelerometry" - has shown that the Jan Medical Nautilus BrainPulse technology has detected a consistent pattern correlated with concussion.
The Revive SE Device from Codman Neuro is designed to ease navigation through small and tortuous blood vessels and arteries in the cerebral vasculature. The new device enables rapid restoration of blood flow to the brain during an acute ischaemic stroke.
The Neuravi Thromboembolic Initiative brings together Neuravi engineers with clinicians and researchers in an effort to deepen the understanding of the mechanical properties of clot and occlusion dynamics, with the goal of improving the physician's ability to restore flow in acute ischaemic stroke.
Manufactured by Biogen Idec, Plegridy was approved on 15 August 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS).
GeNeuro has announced positive results from a one-year, open-label extension of a phase IIa study.
The publication of an independent, prospective validation study has demonstrated the potential clinical utility of the BrainScope technology for the identification of acute traumatic intracranial haematomas in patients who present to hospital emergency departments.
The UK's leading charity for children with brain injury has launched a new three-year strategy, outlining ambitious plans to reach thousands more children and families across the UK.
NICE has approved Tecfidera as an option for treating adults with active relapsing remitting multiple sclerosis.
Physicians from the University of California, San Francisco, USA, report that resection is safe and effective in children with pharmacoresistant focal epilepsy.
The online Registry (www.endALZnow.org) aims to accelerate research by connecting healthy individuals who are committed to preventing Alzheimer's with scientists carrying out the studies.
Medtronic has announced that it has acquired Sapiens Steering Brain Stimulation (Sapiens SBS) for approximately US$200 million in an all-cash transaction.
NeuroSigma has announced that the US Department of the Army, through the US Army Medical Research and Material Command, has funded a phase II clinical trial aimed at examining the use of external eTNS as treatment for post-traumatic stress disorder.
In a recently published article in the journal Neurosurgery the use of VISIUS intraoperative MRI (iMRI) in brain tumour surgery has been proven to result in complete tumour removal in more patients with glioma tumours.
Covidien has announced that it has acquired Reverse Medical Corporation, a privately held medical device company focused on expanding the management of vascular disease. Financial terms of the transaction were not disclosed.
The innovative ultrasound approach uses acoustic pressure to let molecules through-may help treatment for central nervous system diseases like Parkinson's and Alzheimer's.
A University of Utah team discovered a method for turning a small, US$40 needle into a 3D microscope capable of taking images up to 70 times smaller than the width of a human hair.
Three out of four people would want to know what kind of neurological disorder they had even if there was no cure, according to new global research from GE Healthcare.
The first pre-clinical mouse study using ischaemia-tolerant mesenchymal stem cells (itMSCs) shows over 30% decrease in amyloid beta (Abeta) plaques.
electroCore has appointed Piper Jaffray to assist in discussions with pharma companies who are interested in partnering on the commercialisation of its non-invasive vagus nerve (nVNS) stimulation therapy.
Adult smokers with limited education face a greater risk of stroke than those with a higher education, according to new research in the American Heart Association's journal Stroke.
Biogen Idec has announced that the US Food and Drug Administration has approved Plegridy (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis.
Enrolment to the ongoing clinical phase IIa study with NeuroVive's drug candidate NeuroSTAT for treating patients with severe traumatic brain injury is continuing, and another two patients have been enrolled.
The patents cover control of effective MR imaging using a movable system; imaging coils where clarity is maintained when used while in position during X-ray use; and other components related to using both MR and X-ray imaging in the same environment.
NeuroPace has announced that the Centers for Medicare & Medicaid Services (CMS) has approved New Technology Add-on Payments (NTAP) for the RNS system, the world's only commercially available implantable closed-loop responsive neurostimulator system.
AcuteCare Telemedicine continues to expand its presence in the Southeastern region with the addition of new client hospitals.
GE Healthcare has announced that the first integrated, simultaneous, time-of-flight (TOF) capable, whole body Signa PET/MR is 510(k) pending at the US Food and Drug Administration.
Royal Philips and Accenture have announced that they have developed proof of concept software connecting a wearable display to Emotiv Insight Brainware that could ultimately give more independence to patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Neuralstem has announced that the final patient was treated in its phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
NeuroDerm has announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson's disease, eligible for a European Union marketing authorisation application procedure ("centralised procedure").
A Los Angeles team of scientists and surgeons reported that sound registered in the brain of a deaf Canadian boy for the first time after doctors activated a hearing device that had been surgically implanted in his brainstem.
New technology in the form of a magnetically-assisted remote-controlled catheter (MARC) which could allow physicians to see and assess brain tissue more clearly while treating a stroke may hold promise.
The Society of Neurointerventional Surgery (SNIS) Foundation recognised its first Seed Grant awardee with US$25,000 to fund a translational research project.
IMRIS has announced that it has obtained regulatory CE mark for integrating the next generation MRI core technology into the VISIUS surgical theatre allowing for sales and marketing in the European Union.
Medtronic has announced that it has completed the acquisition of Visualase, a privately held company based in Houston, USA, that develops and markets an FDA-approved MRI-guided laser and image guided system for minimally invasive neurosurgeries, including surgical thermal ablation.
NeuroPace has announced its partnership with the Defense Advanced Research Projects Agency (DARPA) Restoring Active Memory (RAM) teams at the University of Pennsylvania and the University of California, Los Angeles (UCLA), USA to develop new treatments for memory deficits using neurostimulation.
Biogen Idec has announced that the European Commission has granted marketing authorisation for Plegridy (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis.
The grant will support preclinical studies evaluating ThermoDox, heat-activated liposomal encapsulation of doxorubicin, in combination with High Intensity Focused Ultrasound (HIFU), for the treatment of brain tumours.
New research provides an intriguing glimpse into the processes that establish connections between nerve cells in the brain. These connections, or synapses, allow nerve cells to transmit and process information involved in thinking and moving the body.
Unclogging the body's protein disposal system may improve memory in patients with Alzheimer's disease, according to a study from scientists at Kyungpook National University in Korea published in The Journal of Experimental Medicine.
Fewer Americans are having strokes and those who do have a lower risk of dying from them finds a new study led by Johns Hopkins Bloomberg School of Public Health researchers.
Georgia Tech researchers have created a mechanical device intended to help stroke victims. Their functional MRI-compatible hemiparesis rehab device creates a long latency stretch reflex at the exact time as a brain signal.
Stroke inpatient rehabilitation facilities yield better neurological outcomes than skilled nursing...
A demographic analysis has revealed that an association exists between discharge disposition and National Institutes of Health Stroke Scores (NIHSS) at 90-day follow-up.
The study is to determine whether two investigational anti-amyloid drugs can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.
The objective of this collaboration is to commercialise a clinical blood test for detecting the earliest stages of Alzheimer's disease as well as mild cognitive impairment.
While the global epidemic of Alzheimer's disease continues to grow, new data on lower incidence in the "youngest old" from developed countries in Europe and the United States suggest the possibility of reducing risk and/or preventing the disease, according to the results of several research studies.
An editorial published in The Lancet Neurology calls for sports authorities to take into consideration the long-term neurological problems that repeated concussions can cause.
Data results found that combination therapy was more effective in removing clumps of amyloid-beta protein in the brain - a component that is thought to lead to Alzheimer’s disease - than use of one therapy.
Cataract surgery for people with Alzheimer’s disease and other dementias not only improves vision but can slow decline in cognition and improve quality of life for both people with the disease and their caregivers, according to clinical trial results reported at the Alzheimer’s Association International Conference 2014 (AAIC) in Copenhagen, Denmark.
Participation in activities that promote mental activity, and moderate physical activity in middle age, may help protect against the development of Alzheimer's disease and dementia in later life according to new research.
A group of leading brain injury specialists look back on 40 years of the Glasgow Coma Scale and outline the continuing role of the scale in research and clinical practice, in a new Personal View published in The Lancet Neurology.
Higher levels of stress, hostility and depressive symptoms are associated with significantly increased risk of stroke in middle-age and older adults, according to new research in Stroke.
This new patent grants six claims surrounding the use of the company's Barrel vascular reconstruction device technology platform.
NeuroSigma has announced that the US National Institutes of Health (NIH) has awarded UCLA a grant that funds a phase II 90-subject paediatric clinical trial focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with the Monarch eTNS system.
According to doctors, the device could offer hope for patients with large, wide-neck brain aneurysms previously considered untreatable.
Neurological scientists at Rush University Medical Center have found that using cinnamon can reverse the biomechanical, cellular and anatomical changes that occur in the brains of mice with Parkinson's disease.
A patient who underwent a less-invasive technique to repair an arteriovenous fistula was able to return to work just two weeks after surgery.
Brainlab has announced the launch of the Right.Brain Foundation, which will provide medical technology and education to selected hospitals and public institutions in Southeast Asia, Africa, Central and South America.
NeuroSigma has announced top-line summaries of presentations made at the 11th European Congress on Epileptology in Stockholm, Sweden, related to the use of external trigeminal nerve stimulation (eTNS) in epilepsy.
Researchers at King's College London and co-funded by Alzheimer's Research UK have announced a panel of 10 proteins that could form a blood test to predict those most likely to develop Alzheimer's.
The Scottish Medicines Consortium (SMC) has published its advice that Lemtrada has been accepted for use within NHS Scotland for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS).
Mazor Robotics has announced that it has received the first order for its Renaissance system since the commercial launch of the brain surgery module.
Patients newly diagnosed with glioblastoma multiforme (GBM) and treated with an experimental cancer vaccine made from the patient’s own tumour in addition to standard of care lived longer compared to those who received standard of care alone, according to new results from a study involving Northwestern Medicine researchers and released on 1 July.
The Apollo system is a new surgical tool that enables minimally invasive removal of deeply seated tissue and fluids in the brain during a single, efficient operation. With combined use of an endoscope and image guidance, the Apollo system allows decompression and removal of otherwise inoperable blood clots deep in the brain, among other uses.
New evidence shows that the omega-3 polyunsaturated fatty acids (PUFAs) found in seafood and marine oils, DHA and EPA, can significantly reduce damage from stroke in a mouse model when given immediately afterwards.
The William Quarrier Scottish Epilepsy Centre (WQSEC), a not-for-profit partnership between charity Quarriers and the NHS, welcomed 96 patients in the 12 months after opening in April 2013, its first annual report has revealed.
Agenus has announced final results from a phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected.
The final tranche of US$15 million of the US$40 million was optional but following discussions between the investors this was not only made compulsory but increased by US$10 million to a total of US$50 million.
A combined approach with the Penumbra aspiration system (Penumbra) and the Solitaire FR retrieval device (ev3, Covidien) has been successfully used in a patient with extensive superior sagittal sinus thrombosis and cortical venous thrombosis, according to a case report.
Brain+, a brain-training programme that outpaces existing apps in engagement, effectiveness and economy for users, is being launched in a brand new version on the 1 July.
Genzyme has announced that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved Lemtrada (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
The Surgical Navigation Advanced Platform (SNAP) integrates with operating room technology to provide advanced 3D capabilities and augmented reality, allowing surgeons to enhance their surgery performance and "see what cannot be seen".
Chinese scientists are planning to build a "brain database" in a bid to identify clues to tackling cerebral diseases and related disorders.
The American Heart Association is funding a new research network to help people make behaviour changes to prevent heart disease and stroke, the two leading causes of death in the world.
Research published in PLOS ONE by researchers at the University of Warwick, UK indicates that sleep problems are associated with worse memory and executive function in older people.
For the first time ever, a paralysed man has moved his fingers and hand with his own thoughts after an electronic neural bypass for spinal cord injuries that reconnects the brain directly to muscles, allowing voluntary and functional control of a paralysed limb. This innovation comes from a partnership between The Ohio State University Wexner Medical Center and Battelle.
Genzyme has announced that it has been shortlisted for a Prix Galien award, in the Innovative Drug Award Category, for its multiple sclerosis therapy Lemtrada.
The study met its endpoint of safety, and also demonstrated a reduction in the number of headache days per month for patients using the active device.
The Ohio Clinical Trials Collaborative (OCTC) has appointed Jill Barnholtz-Sloan as chair of its Neuro-Oncology Working Group.
Neuralstem has announced that two sets of data from the NSI-189 clinical trial in major depressive disorder were reported at two recent academic conferences: American Society of Clinical Psychopharmacology Annual Meeting, and the International College of Neuropyschopharmacology Annual Meeting.
Researchers at the Imperial College London will study individuals with genetic mutations associated with Parkinson's disease as one of 32 clinical sites of the Parkinson's Progression Markers Initiative, a large-scale biomarker study sponsored by The Michael J Fox Foundation for Parkinson's Research.
Lingraphica has introduced the iPad app component of TalkPath Therapy, its integrated cloud-based speech therapy solution for the millions of adults with aphasia write or comprehend language, and the clinicians who work with them to improve language skills.
Neuro Resource Group continues to expand the utilisation of its new InterX 900 ISSDE Pain Management System for post-surgical pain management in hospitals and surgery centres.
Royal Philips has announced the introduction of NeuroSuite, a new integrated solution designed to support and enhance minimally invasive image-guided neurological interventions.
Airo Mobile Intraoperative CT, developed and manufactured by Mobius Imaging and distributed by Brainlab, was awarded gold in the Radiological and Electromechanical Device category of the 17th Annual Medical Design Excellence Awards (MDEA) competition.
Researchers at the Allen Institute for Brain Science have mapped the development of the mouse brain from the embryo to the adult, creating a preliminary genetic key that allows them to pinpoint the age and location of regions of the developing brain.
A study published in the Oxford Journal Neuro-Oncology proved that integrating navigated transcranial magnetic stimulation (nTMS) into the surgical workflow to pre-operatively localise motor function has a significant impact on treatment and outcome.
Neurim Pharmaceuticals has announced publication of the results from an exploratory phase 2 randomised placebo-controlled clinical trial evaluating the safety and efficacy of add-on Circadin (Prolonged Release melatonin 2mg) to standard therapy in Alzheimer’s disease patients.
A case report has described the novel use of a stent for the removal of a foreign body from the cerebrovascular system.
In a new study published online in the Journal of the American Heart Association, researchers at Columbia Engineering report that they have identified a new component of the biological mechanism that controls blood flow in the brain.
Floridian Community Bank has announced that it will sponsor the Nova Southeastern University Concussion Management Clinic, one of the largest community-based sport concussion initiatives in the state of Florida.
Specialists at Northwestern Medicine’s Comprehensive Epilepsy Center recently started using a new surgical procedure that could change the lives of epileptics who are unable to control their seizures with medication.
Patients with Parkinson's disease treated with the Vercise deep brain stimulation system (Boston Scientific) demonstrated a highly significant and consistent improvement in motor scores, according to the latest one-year data.
Expanding on the initiatives of the G8 Dementia Summit held in December 2013, the Global Dementia Legacy Meeting will propose ways to increase and apply investments in dementia.
NeuroTrax has announced the global availability of BrainCare, a cognitive assessment and report solution to aid clinicians in advancing brain wellness of stroke survivors and traumatic brain injury patients.
For long-term treatment of newly diagnosed Parkinson's disease, the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists and monoamine oxidase type B inhibitors, according to a study published in The Lancet.
The CUSTOM-DBS clinical study demonstrated that shorter stimulation pulses may offer a clinical advantage over deep brain stimulation therapy using conventional pulses.
Physicians at Stanford Hospital & Clinics now offer an implantable therapeutic device, designed to detect and treat seizures, for certain patients with epilepsy.
The new microcatheter is designed to mitigate the technical challenges of catheter retrieval during Onyx liquid embolic system embolisations of brain arteriovenous malformations.
In a multicentre, randomised, trial across Europe, electroCore's non-invasive vagus nerve stimulation therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care.
The US Food and Drug Administration (FDA) has expanded the indication for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa to now include adjunct to dopamine agonists. The new indication reflects that Azilect can be used alone or in combination with other Parkinson's disease medications.
The IDE allows Pulsar Vascular to begin a multicentre clinical trial in support of a humanitarian device exemption (HDE) to evaluate the PulseRider for US approval for wide neck aneurysms at or near a bifurcation of the basilar tip or carotid terminus.
For patients with mesial temporal lobe epilepsy (MTLE) that can't be controlled by medications, a minimally invasive laser procedure performed under MRI guidance provides a safe and effective alternative to surgery, suggests a study in the June issue of Neurosurgery.
Researchers report that in a prospective study, the Enterprise stent (Codman) was found to be a safe and effective when used for primary stenting. The findings were published in the Journal of NeuroInterventional Surgery.
The University of Texas Health Science Center at Houston Medical School, in partnership with Memorial Hermann-Texas Medical Center, USA, has announced that the UTHealth Mobile Stroke Unit has successfully transported and helped save the life of its very first patient.
The Allen Institute for Brain Science, Seattle, USA, is embarking on the first effort to map connectivity patterns across the whole brain in mouse models of Alzheimer’s disease, through its recent award of a US$3.4 million grant over five years from the National Institute on Aging of the National Institutes of Health.
The results of the phase II trial show an impressive therapeutic effect of AD04 and make it the first ever compound demonstrating clinical and biomarker evidence consistent with disease modification of Alzheimer's disease.
Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.
Researchers at Shepherd Center, Atlanta, USA, are studying whether stimulating the brain before rehabilitation could yield greater gains in motor function for people recovering from stroke. Researchers believe that the new approach could change common practices of care for certain stroke patients.
Designed to be used independently by anyone seeking to improve brain function or in conjunction with a clinician as an integral part of therapy, this new mobile solution integrates ground-breaking research on brain plasticity and rehabilitation from Boston University (USA) and other leading institutions.
Advanced Brain Monitoring has announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for Night Shift, a therapy for positional obstructive sleep apnoea.
At the biennial meeting of the American Society of Stereotactic and Functional Neurosurgery (31 May-3 June; Washington, DC, USA) Gene Barnett, director of the Rose Ella Burkhardt Brain Tumor and NeuroOncology Center at the Cleveland Clinic, will present his experience utilising NeuroBlate system (Monteris Medical) laser ablation in patients with brain tumours and radiation necrosis.
Phase 1 and phase 2 clinical studies demonstrated promising signs of both central nervous system and peripheral anti-tumour activity of ANG1005 in patients with brain metastases including breast cancer patients.
Genzyme has announced that the US Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA.
IMRIS has announced that the SYMBIS Surgical System - the second generation of the neuroArm / Symbis programme - is a 2014 inductee into the Space Technology Hall of Fame. The Space Foundation honour is directed at technologies originally developed for space exploration that are being transformed into products to help improve the quality of life on Earth.
Teva Pharmaceutical Industries and Active Biotech have announced that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis in the European Union at this time.
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending that Lemtrada should be reimbursed on the National Health Service (NHS), as an option for treating adults with active relapsing remitting multiple sclerosis.
Previous studies have indicated migraine could be an important stroke risk factor for younger people. A new study published in Stroke now says that older migraine sufferers may be more likely to have silent brain injury.
Inovio Pharmaceuticals has announced that it has acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Bin Wang, a professor at Fudan University's Shanghai Medical College.
NeuroQuant enables the acquisition of volumetric brain image data and automatically conducts accurate and consistent measurements of cortical and subcortical volumes targeted at identifying evidence of neurodegeneration. This innovative solution will provide neurologists and radiologists with objective support for their clinical impression.
SpringTMS is the first medical device available to patients in the USA for the acute treatment of pain associated with migraine headache with aura. The device is currently CE marked in Europe and is available to patients in the UK.
As part of the global effort to defeat dementia, around 100,000 participants are expected to be part of the world's most comprehensive imaging project over the next five years, following the launch of a feasibility study.
Neurotrope has signed an agreement with Stanford University to study and, along with Paul Wender, investigate certain analogs of bryostatin, referred to as "bryologs", as potential clinical candidates for the treatment of various neurological disorders.
IMRIS has announced that Barnes-Jewish Hospital in St Louis is the first US hospital to use VISIUS iMRI for more than 1,000 procedures. This clinical experience and published evidence by the neurosurgical team has shown that intraoperative MRI is an effective tool for improving results and outcomes for patients undergoing brain surgery.
Keystone Heart has raised US$14 million in series B funding for cerebral protection devices. By protecting all brain territories, the TriGuard cerebral protection device is designed to minimise the risk of cerebral damage during transcatheter aortic valve implantation (TAVI) and other cardiovascular procedures.
Tobias Pilgaard Ottosen (Department of Clinical Epidemiology, Aarhus University Hospital, Denmark), in a presentation at European Stroke Conference (Nice, France, 6-9 May) told delegates that, over a 30-year period, first-time hospitalisation for subarachnoid haemorrhage has increased.
A poster presented at the European Stroke Conference (6-9 May 2014, Nice, France) by Robbert-Jan van Hooff (Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium) and colleagues reports that surface cooling of the neck with a surface cooling system could contribute to therapeutic hypothermia and neuroprotective effects in acute stroke.
Cyberonics has announced positive results from the Pulse (Open prospective randomised long-term effectiveness) study of vagus nerve stimulation (VNS) therapy in patients with refractory epilepsy conducted at 28 sites in Europe and Canada and published in the journal Epilepsia.
Neuroscientists at SRI International have found that a form of baclofen, a drug used to treat muscle spasticity, works better at treating narcolepsy than the best drug currently available when tested in mice.
Neurosurgeon Steven N Kalkanis has been appointed chair of the Department of Neurosurgery and co-director of the Neuroscience Institute at Henry Ford Hospital in Detroit, USA.
At the joint ISMRM-ESMRMB 2014 meeting (10-16 May, Milan, Italy), Bruker announced a new phased array MRI CryoProbe for in vivo neuroimaging that delivers unparalleled access to rat brain microstructure and biochemistry, previously unresolvable in in vivo imaging of the rat.
Neuronetics announced a new analysis of data at the annual meeting of the American Psychiatric Association that shows transcranial magnetic stimulation (TMS) administered with the NeuroStar TMS therapy system resulted in greater symptom improvement than next-choice conventional anti-depressant medication.
Anakinra (Kineret), an interleukin-1 (IL-1) inhibitor, is now available in the UK for treatment of CAPS in children and adults. Anakinra is the first CAPS treatment licensed for use in infants as young as eight months by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Known as Rowena, the neurological simulator was shortlisted from over 950 entries in the FSB WorldPay UK Business Awards which take place at the Waldorf Hotel in London on 21st May. Rowena was created by consultant neurosurgeon Richard Ashpole, founder of Neurodesign.
Monteris Medical announced that their novel magnetic resonance imaging (MRI)-guided laser technology, the NeuroBlate system, was recently applied by neurosurgeons at UC San Diego Health System to a malignant tumour deep inside a patient's brain.
The US$1.1 million was generated during the "Fund a Scientist" auction at its Eighth Annual Connoisseur’s Dinner on May 1, 2014, and awarded to Jeffrey Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio, USA. Cummings will investigate rasagiline, an FDA-approved treatment for Parkinson’s disease with the potential to be the first drug to slow the course of Alzheimer’s disease.
The research collaboration with Cleveland Clinic will be focused on developing new therapeutic approaches to the treatment of multiple sclerosis.
At the American Association of Neurology (AAN) meeting in Philadelphia, USA, two separate studies showed that electroCore's non-invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migraine.
Lpath has received official notification from the National Institutes of Neurological Diseases and Stroke (NINDS) that it has been awarded a US$1.7 million, 2.5-year grant to develop its antibody therapeutic, Lpathomab, which is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury.
Functional Neuromodulation has completed enrolment for the Advance study. Forty-two North American patients with mild Alzheimer's have had a deep brain stimulation system implanted to evaluate the safety and potential clinical benefit of deep brain stimulation of the fornix.
Synthetic Biologics reports that the University of California, Los Angeles (UCLA) School of Medicine (USA) has announced preliminary, positive top-line data from the phase II clinical trial evaluating Trimesta (oral estriol), an oral, once-daily treatment for relapsing-remitting multiple sclerosis in women.
In a paper published in the Journal of Pain it was reported that electroCore's non-invasive vagus nerve stimulation (nVNS) therapy can significantly reduce excessive glutamate levels in key regions of the central nervous system of animals sensitised to experience migraine-like symptoms.
The results of a two-year human clinical study have been published in the American Heart Association journal, Stroke. The results show that vitamin E tocotrienols derived from Malaysian palm oil may support white matter health by weakening the progression of white matter lesions.
One of the first studies to look at a relationship between death and the two types of mild cognitive impairment suggests that people who have thinking problems but their memory is still intact might have a higher death rate in a period of six years compared to those who have no thinking or memory problems.
Lpath and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), USA, have initiated a study on the use of Lpathomab, an antibody to lysophosphatidic acid (LPA), in the treatment of brain injury induced by blast overpressure.
AdvaStim has announced that it has entered the research and development market with a new hardware/software solution for neuromodulation therapy developers.
IMRIS has announced that a University of South Florida neurosurgical team at Tampa General Hospital (TGH), USA, completed initial cases last week using its recently installed VISIUS intraoperative MRI. The first case was a right parietal high-grade glioma.
Researchers from the Oxford Martin School, University of Oxford, UK, are calling for the regulation of a new breed of devices designed to enhance the brain's performance. According to Oxford Martin School, these devices, because of European legislation, only receive basic product safety requirements.
Researchers from NeuroPhage Pharmaceuticals have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterised by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases, according to a press release.
For the first time, researchers have demonstrated that asymptomatic carotid stenosis may be linked to problems in learning, memory, thinking and decision-making, compared to people with similar risk factors but no carotid stenosis.
IMRIS has announced that a study published in the journal Neurosurgery by the neurosurgical team at Cleveland Clinic (USA) adds to growing clinical evidence which validates use of high-field intraoperative MRI (iMRI) as an effective tool for maximising the amount of surgical resection of gliomas.
A functional brain imaging technique, positron emission tomography (PET), is a promising tool for determining which severely brain damaged individuals in vegetative states have the potential to recover consciousness, according to new research published in The Lancet.
The Scottish Medicines Consortium (SMC) has approved Tecfidera (dimethyl fumarate) as a first-line oral treatment for people with relapsing-remitting multiple sclerosis.
Elekta, Royal Philips and University Medical Center Utrecht (the Netherlands) announced that the initial components of the world's first high-field magnetic resonance imaging (MRI) guided radiation therapy system are being installed at University Medical Center Utrecht.
Boston Scientific has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise deep brain stimulation system in patients with Parkinson's disease.
Covidien has announced that it has notified customers of a voluntary recall to address an issue with certain lots of its Pipeline embolisation device and Alligator retrieval device where the polytetrafluoroethylene (PTFE) coating applied to the delivery wire could delaminate and detach from the devices.
Brainlab and Mobius Imaging announced CE mark approval for Airo mobile intraoperative computed tomography. The CE mark allows Brainlab to begin installation of the systems sold in the European Union.
NeuroSigma announced that it has received approval from the Therapeutic Goods Administration (TGA) to market its Monarch eTNS (external trigeminal nerve stimulation) system in Australia. The approval allows NeuroSigma to market the Monarch eTNS system for the adjunctive treatment of drug-resistant epilepsy in patients nine years of age and older.
Cognition Therapeutics has received a US patent for a drug to fight Alzheimer's disease. The patent describes the discovery of several candidate drug molecules which can stop the effects of the brain protein that appears to play a major role in development of Alzheimer’s disease.
The Society of NeuroInterventional Surgery and M2S announced the launch of the NeuroVascular Quality Initiative, a multi-module registry system designed to track performance and outcomes data across a variety of neurovascular conditions. The launch debuts the Acute Ischaemic Stroke module, which will be used to track and benchmark clinical performance at the centre level and nationally.
The combination of the IMRIS Visius surgical theatre and the ClearPoint neuro intervention system provided continuous real-time visualisation and guidance throughout a neurosurgical intervention to treat a brain tumour.
Researchers at The Center of Free Radical and Biomedical Research at Facultad de Medicina, Universidad de la Republicain Uruguay announced the discovery that the antioxidant MitoQ prolonged the lifespan and health-span of mice suffering from amyotrophic lateral sclerosis-like (ALS) disease, and successfully improved functional parameters related to muscular strength and reversed mitochondrial damage in nervous and muscle tissue.
Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
In a study conducted by William Mehan et al, it was found that for patients with unruptured intracranial aneurysms, multilobulated morphology and interval growth of the unruptured aneurysms are "characteristics predictive of a higher risk of subsequent rupture during conservative CT angiography (CTA) follow-up."
A direct aspiration first pass technique (ADAPT) with a large bore aspiration catheter has been shown to be "fast, safe, simple and effective method" for acute ischaemic stroke thrombectomy. The results were published in the Journal of of NeuroInterventional Surgery.
In a two-year clinical trial involving 140 patients with secondary progressive multiple sclerosis, the drug simvastatin slowed brain shrinkage, which is thought to contribute to patients' impairments.
St Jude Medical has received CE mark approval for its Prodigy chronic pain system with burst technology, the first and only implantable neuromodulation system that delivers burst stimulation.
A new paper published by a joint US and Canadian team in PLOS One suggests SPECT (single photon emission computed tomography)-a functional brain imaging modality that produces images of blood flow to the brain, showing areas of over or under-activity-is useful in both identifying and guiding treatment for those with traumatic brain injuries.
Avanir Pharmaceuticals announced the presentation of results from a first-of-its-kind study of pseudobulbar affect (PBA) symptoms in veterans with mild traumatic brain injury conducted in collaboration with the Department of Veterans Affairs and Evidera.
The US Food and Drug Administration (FDA) has approved marketing of Cefaly, the first device as a preventative treatment for migraine. This is also the first transcutaneous electrical nerve stimulation (TENS) device specifically authorised for use prior to the onset of pain.
IMRIS announced that neurosurgeons at Dartmouth-Hitchcock Medical Centre in Lebanon, USA, have completed several cases to inaugurate use of intraoperative MRI (iMRI) within the Visius surgical theatre inside the hospital's Centre for Surgical Innovation.
The final results from the phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS) were published in the peer-reviewed journal, Annals of Neurology.
Every 15-minute delay in delivering a clot-busting drug after stroke robs survivors of about a month of disability-free life, according to a new study in the American Heart Association journal Stroke.
In a recent study it was found that ice hockey players in Sweden with a sports-related concussion had higher levels of the blood biomarker total tau (T-tau), which suggests the central nervous system protein may be a tool for diagnosing concussions and making decisions about when players can return to play.
Philips has launched a campaign for 2014 which highlights sleep as a powerful engine for all our daily activities.
A recent study has found that neuroimaging for headaches is frequently ordered by physicians during outpatient visits, despite guidelines that recommend against such routine procedures.
A new study shows that extreme sports such as snowboarding and skateboarding present high risk for head and neck injuries, including concussions. The findings support need for greater education and advocacy efforts for safer equipment.
A study reported in the International Headache Society's official journal Cephalalgia found that the use of electroCore's non-invasive vagus nerve stimulation therapy may be an effective and well tolerated treatment for migraine in certain patients.
A new study presented at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found no link between neurocognitive function and years of football play in adolescent athletes.
The 24-month results of a prospective European clinical study using Nevro Corp's Senza system delivering HF10 therapy were published in the journal Pain Medicine. The study was conducted in the UK and Belgium with 65 of the 72 implanted patients (90%) being available for data collection at two years.
NeuroDerm announced that enrolment of patients is ongoing in its second phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.
The new once daily, first-line oral treatment can be offered as an alternative to currently available injectable treatment options for people with an active relapsing remitting form of multiple sclerosis.
Northwest Biotherapeutics has announced that the Data Safety Monitoring Board has made an unblinded review of the safety data for the company's ongoing international Phase III Glioblastoma multiforme (GBM) Trial, and has recommended that the trial continue as planned.
Published in the Journal of NeuroInterventional Surgery, the results of a small study of 11 patients has demonstrated that Silk flow diverter stents (Balt Extrusion) could be a safe and feasible treatment for fragile, difficult-to-treat blood blister-like aneurysms.
The brain research discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's disease, chronic traumatic encephalopathy and traumatic brain injury.
Stem cell research institute of STC Life and 97.7 B&H Clinic successfully completed mesenchymal stem cell treatment for stroke patients.
D-Pharm has reported the successful interim analysis of its phase II clinical study of THR-18 in acute stroke patients treated with the thrombolytic drug tPA.
CEL-SCI Corporation announced its phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, injection) has activated its first US clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina, USA.
Forest Laboratories and Adamas Pharmaceuticals announced Forest's submission of a new drug application to the US Food and Drug Administration for a fixed-dose combination of memantine HCl extended release and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer's type.
Lpath has brought scientists one step closer to finding a potential treatment for traumatic brain injury with a recent publication showing that Lpathomab, an anti-lysophosphatidic acid antibody, reverses much of the damage caused by trauma to the nervous system.
Intra-Cellular Therapies announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer’s disease.
University of Leicester scientists will showcase their research findings as part of Brain Awareness Day on Wednesday, 12 March
Clinicians prescribed opioids for almost half of the teenagers they treated for headache when medications, such as aspirin, ibuprofen and naproxen, are recommended as first-line therapies, according to a study in the Journal of Adolescent Health.
The aim of these partnerships between Dystonia Europe and the European Parkinson's Disease Association and Boston Scientific is to increase awareness, understanding of solutions and to take initiatives in the worldwide fight against Parkinson's disease and dystonia, two areas of high unmet need.
NeuraCeq (florbetaben 18F) has been approved for PET imaging of beta-amyloid neuritic plaque density in the brain.
An antibody found in the blood of people with multiple sclerosis may be present long before the onset of the disease and its symptoms, according to a recent study that will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, USA, April 26 to May 3, 2014.
The Global CEO Initiative (CEOi) on Alzheimer's Disease announced that Takeda Pharmaceutical Company will join the CEOi as part of its effort to spur innovations in research and accelerate a means of prevention for Alzheimer's and dementia, building momentum behind the G8's commitment to stop the disease by 2025.
Vitae Pharmaceuticals announced that it has earned a US$14 million milestone payment from Boehringer Ingelheim for that company’s initiation of a Phase I clinical trial in the Vitae’s beta-secretase (BACE) inhibitor programme for Alzheimer’s disease.
Stryker has launched the Trevo XP ProVue retrieval system, a second generation fully visible stent retriever to treat acute ischaemic stroke.
Ezose Sciences has announced that it has received a grant from the Michael J Fox Foundation for Parkinson's Research to apply Ezose's GlycanMap technology to investigating the role of the sugars known as glycans in Parkinson's disease.
The stem cell research institute of STC Life and 97.7 B&H Clinic successfully completed mesenchymal stem cell therapy for patients with Parkinson's disease.
Reverse Medical Corporation has announced the initial clinical use of their UNO neurovascular embolisation system for intracranial use. The device has been granted European Union CE mark approval to obstruct blood flow in the neurovasculature.
Berg and the Parkinson's Institute and Clinical Centre has announced the next phase in their ongoing partnership, focused on identifying potential biomarkers that may lead to breakthroughs in the research, diagnosis, and treatment of Parkinson's disease.
The IMRIS horseshoe headrest provides non-rigid head positioning for paediatric and adult patients during brain surgery and intraoperative imaging in the VISIUS surgical theatre.
Ornim Medical has announced that new study results demonstrate the feasibility of the Cerox cerebral oxidation monitor for measuring regional cerebral tissue oxygenation in patients with severe traumatic brain injury.
IMRIS has announced US Food and Drug Administration (FDA) clearance of the newest generation VISIUS surgical theatre which integrates Siemens' latest high-field magnetic resonance (MR) scanners for use during neurosurgical procedures.
New stroke therapy, using a combination of non-invasive navigated transcranial stimulation along with occupational therapy, has been found to produce significant gains in motor function post-stroke, with an average of 50% of stroke survivors recovering full use of their arm.
Constant Therapy, a developer of a cloud-based iPad solution enabling people with cognitive, language, communication and learning disorders to access science-based brain therapies, has announced that John Gabrieli, Massachusetts Institute of Technology (MIT) Brain and Cognitive Sciences professor, has joined the company's Scientific Advisory Board.
Codman Neuro announced that the US Food and Drug Administration (FDA) has classified the recently initiated medical device correction notice related to the Trufill n-BCA liquid embolic system as a Class I recall.
A build-up of plaque in the carotid artery above the neck was associated with an increased risk of stroke for older white patients in a recent study.
InspireMD has announced that its new CGuard carotid embolic protection system, designed to trap the debris that can travel downstream after a patient is treated with traditional stenting methods, has been successfully implanted in recent procedures.
The Brain Research Foundation has announced the 2014 Scientific Innovations Awards to fund ground-breaking work in Parkinson's disease, epilepsy, Hurler syndrome and autism.
A Norwegian study has found that cerebral, regional magnetic resonance imaging (MRI) can lead to an increase in incidence rates of intracranial tumour diagnosis.
British-born neuroscientist honoured by Vilcek Foundation.
Five new grants have been awarded to investigate the causes of and treatments for amyotrophic lateral sclerosis
The European Commission has approved Tecfidera (dimethyl fumarate) as a first-line oral treatment for multiple sclerosis.
A US team of dementia experts will visit Russia to share experiences in phase III clinical research study.
BrainStorm Cell Therapeutics has signed a definitive agreement with the Mayo Clinic to conduct Phase II of its ALS clinical trial.
The results of a study published in the Journal of NeuroInterventional Surgery have shown that carotid stenting without post-dilation is safe and effective.
The Myelin Repair Foundation has announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) to assess MRF-008, as a potential therapeutic for multiple sclerosis. The NIH are expect to instigate a clinical trial to assess this.
A new funding collaboration to support a clinical trial investigating the potential for hypertension drugs to slow Alzheimer's disease progression has been announced between The Alzheimer's Drug Discovery Foundation of Canada and The W Garfield Weston Foundation.
New data has been reported supporting the clinical validation of MS Precise (DioGenix), a next-generation sequencing assay for the identification of patients with multiple sclerosis at first clinical presentation.
eNeura has reported that it has filed a 510(k) with the US Food and Drug Administration (FDA) for the SpringTMS transcranial magnetic stimulation (TMS) device. SpringTMS is CE marked in Europe and available by prescription in the UK.
Brain surgeon Hrayr Shahinian (the Skull Base Institute, Los Angeles, USA), a pioneer in minimally invasive surgery, and NASA's Jet Propulsion Laboratory in Pasadena, USA, have introduced the next generation of high-tech surgical instruments to remove tumours and treat other brain abnormalities.
Time is of the essence when treating head injuries to avoid potentially serious complications, including disability or death, says the National Institute for Health and Care Excellence (NICE). Its updated guidance on the issue emphasises the importance of early detection and prompt treatment for both children and adults who have suffered trauma to the head.
The study, published in PlosOne, is the first study to use neuroimaging to investigate aspects of cognitive fatigue. The findings of the study support the part that the striato-thalamic-frontal cortical system plays in fatigue, suggesting a "fatigue-network" in multiple sclerosis.
In NHS guidance, the National Institute for Health and Care Excellence (NICE) has announced the results from clinical trials investigating a portable transcranial magnetic device for the treatment of migraine.
In final guidance, the National Institute for Health and Care Excellence (NICE) has recommended the use of Genzyme's multiple sclerosis drug teriflunomide (also called Aubagio) for adults with relapsing-remitting multiple sclerosis.
Concussions are common among middle-school girls who play soccer, and most continue to play with symptoms, according to a study published in JAMA Pediatrics and by John W O' Kane, University of Washington Sports Medicine Clinic, Seattle, USA, and colleagues.
Vitamin D status appears to be associated with reduced disease activity in patients with multiple sclerosis and a slower rate of disease progression, according to a study by Alberto Ascherio, Harvard School of Public Health, Boston, USA, and colleagues.
Stephen M Rao has been named the new editor-in-chief of the Journal of the International Neuropsychological Society (JINS). Rao is the pioneer of the application of task-activated MRI and has applied this strategy to brain mapping for neurodegenerative conditions.
Top Gear presenter Richard Hammond is backing the launch of a book launch aimed at helping youngsters and their parents to better understand brain injuries and their hidden effects, it was reported in a press release from the Children's Trust.
A study from Australia, published online first in BMC Psychology, has confirmed the effectiveness a new test for Alzheimer's disease. The test is said to detect cognitive decline in patients by scoring attention/reaction and learning/memory and comparing the scores to traditional cognitive impairment indicators.
Stryker and NeuroLogica have announced an exclusive partnership agreement in which Stryker will promote and sell NeuroLogica's BodyTom portable full-body computed tomography (CT) scanner for the specialties of neurosurgery, spine surgery, orthopaedic surgery, and trauma surgery in conjunction with the Stryker NAV3i surgical navigation platform.
Results of an internal study of 40 worldwide Visius surgical theatre hospital customers indicates that nearly 13,000 patients have been treated using intraoperative MRI (iMRI) since the first installation in 2005.
The Society of NeuroInterventional Surgery (SNIS) on 9 January has launched a 2014 national tour that will bring together physicians and medical personnel across the USA involved in stroke care to address current stroke treatment and the value of neurointerventional therapy in optimal stroke care delivery.
University Medical Center Hamburg-Eppendorf, Germany, is now offering the use of the EBS Next Wave brain stimulation device designed to expand the visual field of patients with impaired vision caused by optic nerve damage, it was announced by EBS Technologies.
The SunTech Medical Oscar 2 ambulatory blood pressure monitoring system has been selected by PRA for use in a phase I clinical study. The study will investigate the inhibition of degenerative mechanisms to provide improved neuroprotection for those with Alzheimer's disease.
A clinical research study of a non-invasive intracranial pressure measurement device has been launched by the National Space Biomedical Research Institute (NSBRI) and Vittamed, the developer of the device. The study will include the monitoring of neurological patients, as a prelude to possible future use with astronauts.
Apeiron has announced the signing of two transactions as part of the worldwide commercialisation of APN311, an antibody-based immunotherapy in development for the treatment of children suffering from high-risk neuroblastoma.
New findings published in JAMA Neurology from research into a potentially protective therapy for Parkinson's disease show that with medical supervision, urate levels may safely be raised while mitigating risk of complications such as gout. Previous research showed that higher levels of the antioxidant urate were associated with lower risk and slower progression of the disease.
BioCrea announced on 9 January that the Epilepsy Foundation (USA) has presented the Epilepsy Innovation Seal of Excellence Award to BioCrea in recognition of the creation of the new anti-seizure platform, GABAA PAMs (LT GABAA PAM), to treat refractory epilepsy.
TauRx Therapeutics has expanded its international clinical trials by adding new research centres across the USA. The company says the addition of 35 clinical research centres means that more patients suffering from mild or moderate Alzheimer’s, and their caregivers, will have an opportunity to see if they qualify for participation in TauRx’s Alzheimer’s clinical trials.
Researchers at Albert Einstein College of Medicine of Yeshiva University, New York, USA, in cooperation with Resurrecting Lives Foundation, are investigating the effect of repeated combat-related blast exposures on the brains of veterans.
The first patient was treated in the phase I/II NSI-566 stem cell trial to treat motor deficits from ischaemic stroke at BaYi Brain Hospital in Beijing, China, according to a press release.
A new study published in Stroke has identified that there is a higher risk of stroke in people with high levels of anxiety.
Scientists at the University of Kansas School of Medicine and Case Western Reserve University have developed a lightweight, battery-powered device that appears capable of repairing damaged pathways in the brain. The technology holds promise helping individuals who suffer from the damage left by stroke or head injuries.
The Cerena Transcranial Magnetic Stimulator (TMS) from eNeura Therapeutics is a prescription device used after the onset of pain associated with migraine headaches preceded by an aura.
New findings from the Parkinson Alliance show that falls are highly prevalent in Parkinson's disease and may be adversely impacted by deep brain stimulation therapy.
Alzheimer’s Association president and CEO Harry Johns presented and participated in the first ever G8 Dementia Summit hosted by the UK. World leaders acknowledged that the Alzheimer’s and dementia crisis cannot be ignored. All of the G8 countries committed to the goal of identifying disease-modifying therapies or a cure for dementia by 2025.
BrainStorm Cell Therapeutics has announced that the preliminary findings from the ongoing phase IIa dose-escalating trial evaluating NurOwn technology was presented at the 24th International Symposium on ALS/MND in Milan, Italy.
Heptares Therapeutics has announced that it has initiated a phase I clinical study of HTL9936, the first fully-selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate using the Heptares GPCR structure-based drug-design (SBDD) platform.
Stroke deaths in the USA have declined dramatically in recent decades due to improved treatment and prevention, according to a statement published in Stroke.
The ALS Therapy Development Institute (ALS TDI) and Anelixis Therapeutics have announced that it has formed a research partnership with Neurimmune to advance potential treatments for amyotrophic lateral sclerosis (ALS).
On 5 December, the company Functional Neuromodulation reported that 30 patients with mild Alzheimer's disease have been successfully implanted in the ongoing Advance study.
Imris and MRI Interventions announced that Cook Children's Medical Center in Fort Worth, USA, is the first US paediatric hospital to offer asleep deep brain stimulation surgery to children suffering from dystonia by utilising the combination of MRI Interventions' ClearPoint Neuro Intervention System and an Imris Visius Surgical Theatre for real-time intraoperative image guidance and procedure visualisation.
The first US implants of a novel deep brain stimulation system in research that is investigating the brain's response to the therapy has been announced by Medtronic.
A new study shows that a neurologist in an office thousands of miles away can deliver effective specialised care to people with Parkinson's disease. For patients with the condition, these "virtual house calls" could allow them to live independently while effectively managing the symptoms of the disease.
St Jude Medical has initiated a clinical study of the Prodigy neurostimulator, the first spinal cord stimulation system able to deliver a proprietary mode of stimulation therapy called burst stimulation. The study will evaluate whether burst stimulation can be more effective in managing chronic pain than traditional tonic stimulation.
A presentation at ESMINT (5-8 September, Nice, France) says that there are studies that indicate the benefit of mechanical thrombectomy if it is performed with a collaborative team of interventional neuroradiologists, neurologists and neurosurgeons and in dedicated stroke centres. Read more
New retrospective data highlighting the Precision Spectra Spinal Cord Stimulator (Boston Scientific) System demonstrate the device provided highly significant pain relief three months after implantation. The results were presented at the North American Neuromodulation Society (NANS) 17th annual meeting in Las Vegas, USA (5-8 December).
Electrosonic stimulation as adjunctive therapy shows “significant improvements” in Parkinson’s disease...
A presentation on electrosonic stimulation as adjunctive therapy to dopaminergic treatments at the 5th International Symposium on Neuromodulation says that patients undergoing stimulation with the ESStim technology (Highland Instruments) saw significant improvements relative to baseline measurements when compared to sham stimulation in Parkinson's disease patients.
Using a novel stroke rehabilitation device that converts an individual's thoughts to electrical impulses to move upper extremities has reported improvements in stroke patients' motor function and ability to perform day-to-day activities. Results of the study were presented at the annual meeting of the Radiological Society of North America (RSNA; 1-6 December, Chicago, USA).
Genzyme has announced that Health Canada has approved Aubagio (teriflunomide) 14mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Fudan University (Shanghai, China) neurosurgeons have received a journal award at the Congress of Neurological Surgeons annual meeting for high-ranking clinical research using Visius Surgical Theatre for glioma tumours.
Premature birth appears to trigger developmental processes in the white matter of the brain that could put children at higher risk of problems later in life, a study presented at the annual meeting of the Radiological Society of North America (RSNA; 1-6 December, Chicago, USA) says.
The Parkinson's Institute and Clinical Center, Sunnyvale, USA, says that they, in partnership with Population Diagnostics, have discovered a number of new genes relevant to the cause of Parkinson's disease.
A study, published online first in the Journal of Neurointerventional Surgery has found that a single coaxial dual balloon microcatheter can be used to achieve coil placement and neck remodelling in selected oblong intracranial and cervical arterial aneurysms.
The Vercise deep brain stimulation system (Boston Scientific) has received CE mark approval for the treatment of intractable primary and secondary dystonia.
Ashai Intecc has announced the introduction and launch of an innovative neurovascular guidewire, Asahi Chikai black 18, in Japan. The company states that it plans to begin distributing the neurovascular guidewire in December.
Revalesio announced on 11 November a new collaboration with neurologist Roland Martin, head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich, Switzerland. Martin is to conduct a phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis (RRMS).
A new technology that will enable patients suffering from Amyotrophic lateral sclerosis (ALS)-also known as Lou Gehrig's Disease-to communicate via brain monitor, will hold its first clinical trials in Philadelphia, USA. The announcement was made at the BrainTech Israel conference in Tel Aviv (14-15 October).
IMRIS and Stryker have announced a non-exclusive collaboration of automatic image registration for spinal and cranial navigated procedures and VISIUS iCT and VISIUS iMRI surgical suites from IMRIS.
Sapiens Steering Brain Stimulation (Sapiens) Advisory Board has appointed Jan C M Keltjens as the new president and CEO of the company, effective 21 October 2013.
Investigators at Boston Children's Hospital (Boston, USA) report that many infants dying suddenly and unexpectedly, in all kinds of sleep environments, have underlying brainstem abnormalities and are not all normal prior to death.
Toshiba Medical Systems has announced a research partnership with the Walton Centre (Liverpool, UK) to investigate new developments in neuroscience scanning applications and protocols. The research will be undertaken using Toshiba's Aquilion One CT scanning technology, acquired by the Walton Centre to provide data on a series of neuro applications.
According to a recent study conducted at Cincinnati Children’s Hospital Medical Center, USA, high-school athletes who play collision sports at higher altitudes are less likely to suffer from concussions than those who play at lower altitudes.
Mentice announced on 15 November the release of the world's first solution to allow physicians to import medical-image data from cerebral anatomies of real patients into a simulated environment for the purpose of hands-on preparation and training.
A novel drug which assists neurosurgeons to better visualise and remove malignant brain tumours has been approved by the Therapeutic Goods Administration (TGA).
Older men who walked at least one to two hours each day compared to less than half an hour per day had a reduced risk of stroke, a large population-based study reported in Stroke says.
The US Food and Drug Administration (FDA) have approved the RNS Stimulator (Neuropace) to help reduce the frequency of seizures in epilepsy patients who have not responded well to medications.
The largest international study ever conducted on Alzheimer's disease, the International Genomics Alzheimer's Project (I-GAP) consortium has identified 11 new regions of the genome involved in the onset of this neurodegenerative disease.
The study supports growing evidence pointing to glucose levels and vascular damage as contributors to the progression of the deadly form of dementia.
Reverse Medical has announced CE mark approval, FDA 510k clearance and initial clinical use of their Reverse microcatheter product line for intracranial neurovascular use.
The Derivo device is intended for the treatment of patients with intracranial aneurysms who cannot be treated with current endovascular techniques or for patients who would have a high treatment risk with other endovascular or neurosurgical techniques.
According to recent research published in the September 2013 edition of Journal of Stroke and Cerebrovascular Diseases, patients see better results when they receive endovascular treatment at a dedicated stroke centre.
Patients can now undergo asleep deep brain stimulation, under general anaesthesia, due to a revolutionary new platform called the ClearPoint Neuro Intervention System (MRI Interventions) that allows neurosurgeons to conduct the minimally invasive surgery inside an MRI scanner.
A study published this week in PLOS Medicine reports the most recent and comprehensive estimates on how much death and disability is attributable to depression, both worldwide and in individual countries and regions.
Measuring the time it takes a person with multiple sclerosis to walk 25 feet may provide a clear picture of the progression of the disease, along with the severity of disability, according to a study published in the 30 October 2013 online issue of Neurology.
The US Food and Drug Administration has approved Vizamyl (flutemetamol F 18 injection), a radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease and dementia.
Even for elderly people with no signs of dementia, those with hardening of the arteries are more likely to also have the beta-amyloid brain plaques that are a hallmark of Alzheimer's disease, according to a study published in the 16 October 2013 online issue of Neurology.
CHIMES is placebo-controlled trial of NeuroAiD. It has included 1,099 patients with ishaemic stroke who are receiving appropriate secondary prevention treatments. The frequency of early cardiovascular events and deaths during the three-month follow-up was halved in the NeuroAiD, group (p=0.025) without an increase in bleeding rate and non-vascular deaths.
Pulsar Vascular announced that it has received European CE mark approval for Pulserider. This unique implant is used to bridge the neck of cerebral aneurysms previously not amenable to endovascular therapy. This new device is implanted via standard, minimally invasive, endovascular techniques thus providing an alternative treatment option to open surgery.
A team of paediatric neurosurgeons and neuroradiologists at the Johns Hopkins Children's Center has developed a way to minimise dangerous radiation exposure in children with a con